Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Low levels of alitretinoin in seminal fluids after repeated oral doses in healthy men.

Schmitt-Hoffmann AH, Roos B, Sauer J, Brown T, Weidekamm E, Meyer I, Schleimer M, Maares J.

Clin Exp Dermatol. 2011 Apr;36 Suppl 2:12-7. doi: 10.1111/j.1365-2230.2011.04032.x.

PMID:
21443599
2.

Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate.

Schmitt-Hoffmann AH, Roos B, Sauer J, Schleimer M, Schoetzau A, Leese PT, Weidekamm E, Maares J.

Clin Exp Dermatol. 2011 Apr;36 Suppl 2:4-11. doi: 10.1111/j.1365-2230.2011.04031.x.

PMID:
21443598
3.

Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.

Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E, Brown T, Roehrle M.

Antimicrob Agents Chemother. 2006 Jan;50(1):286-93.

5.

Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer.

Camidge R, Reigner B, Cassidy J, Grange S, Abt M, Weidekamm E, Jodrell D.

J Clin Oncol. 2005 Jul 20;23(21):4719-25.

PMID:
16034047
6.

Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.

Schmitt-Hoffmann A, Nyman L, Roos B, Schleimer M, Sauer J, Nashed N, Brown T, Man A, Weidekamm E.

Antimicrob Agents Chemother. 2004 Jul;48(7):2576-80.

7.

Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.

Schmitt-Hoffmann A, Roos B, Schleimer M, Sauer J, Man A, Nashed N, Brown T, Perez A, Weidekamm E, Kovács P.

Antimicrob Agents Chemother. 2004 Jul;48(7):2570-5.

8.

Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.

Reigner B, Watanabe T, Schüller J, Lucraft H, Sasaki Y, Bridgewater J, Saeki T, McAleer J, Kuranami M, Poole C, Kimura M, Monkhouse J, Yorulmaz C, Weidekamm E, Grange S.

Cancer Chemother Pharmacol. 2003 Sep;52(3):193-201. Epub 2003 May 29.

PMID:
12783206
9.

Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.

Poole C, Gardiner J, Twelves C, Johnston P, Harper P, Cassidy J, Monkhouse J, Banken L, Weidekamm E, Reigner B.

Cancer Chemother Pharmacol. 2002 Mar;49(3):225-34. Epub 2002 Jan 10.

PMID:
11935215
10.

Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.

Dingemanse J, Bodin F, Weidekamm E, Kutz K, van Giersbergen P.

J Clin Pharmacol. 2002 Mar;42(3):283-9.

PMID:
11865964
11.

Clinical pharmacokinetics of capecitabine.

Reigner B, Blesch K, Weidekamm E.

Clin Pharmacokinet. 2001;40(2):85-104. Review.

PMID:
11286326
12.

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.

Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B.

Cancer Chemother Pharmacol. 2000;45(4):291-7.

PMID:
10755317
13.

Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.

Cassidy J, Twelves C, Cameron D, Steward W, O'Byrne K, Jodrell D, Banken L, Goggin T, Jones D, Roos B, Bush E, Weidekamm E, Reigner B.

Cancer Chemother Pharmacol. 1999;44(6):453-60.

PMID:
10550565
14.

Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.

Twelves C, Glynne-Jones R, Cassidy J, Schüller J, Goggin T, Roos B, Banken L, Utoh M, Weidekamm E, Reigner B.

Clin Cancer Res. 1999 Jul;5(7):1696-702.

15.

Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients.

Reigner B, Clive S, Cassidy J, Jodrell D, Schulz R, Goggin T, Banken L, Roos B, Utoh M, Mulligan T, Weidekamm E.

Cancer Chemother Pharmacol. 1999;43(4):309-15.

PMID:
10071982
16.

Lack of bioequivalence of a generic mefloquine tablet with the standard product.

Weidekamm E, Rüsing G, Caplain H, Sörgel F, Crevoisier C.

Eur J Clin Pharmacol. 1998 Oct;54(8):615-9.

PMID:
9860148
17.

Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function.

Hoogkamer JF, Kleinbloesem CH, Ouwerkerk M, Högemann A, Nokhodian A, Kirch W, Weidekamm E.

Eur J Clin Pharmacol. 1998 Jun;54(4):341-5.

PMID:
9696961
18.

Pharmacokinetics and pharmacodynamics of mibefradil in hypertensive patients with varying degrees of renal insufficiency.

Welker HA, Weidekamm E, Houwing N, de Chatel R.

Pharmacology. 1998 Jun;56(6):297-307.

PMID:
9654216
19.

Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.

Reigner B, Verweij J, Dirix L, Cassidy J, Twelves C, Allman D, Weidekamm E, Roos B, Banken L, Utoh M, Osterwalder B.

Clin Cancer Res. 1998 Apr;4(4):941-8.

20.

Tolerability and pharmacokinetics of Ro 42-1611 (arteflene) in man.

Weidekamm E, Dumont E, Jaquet C.

Trop Med Parasitol. 1994 Sep;45(3):278-83.

PMID:
7899804
21.

Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.

Schrenzel J, Cerruti F, Herrmann M, Leemann T, Weidekamm E, Portmann R, Hirschel B, Lew DP.

Antimicrob Agents Chemother. 1994 Jun;38(6):1219-24.

22.

Pharmacokinetics of brodimoprim.

Weidekamm E.

J Chemother. 1993 Dec;5(6):475-9.

PMID:
8195840
23.

Influence of rifampin on fleroxacin pharmacokinetics.

Schrenzel J, Dayer P, Leemann T, Weidekamm E, Portmann R, Lew DP.

Antimicrob Agents Chemother. 1993 Oct;37(10):2132-8.

24.

Penetration of fleroxacin into body tissues and fluids.

Weidekamm E, Portmann R.

Am J Med. 1993 Mar 22;94(3A):75S-80S.

PMID:
8452186
25.

Pharmacokinetics of fleroxacin in renal impairment.

Weidekamm E.

Am J Med. 1993 Mar 22;94(3A):70S-74S.

PMID:
8452185
26.

Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women.

Dan M, Weidekamm E, Sagiv R, Portmann R, Zakut H.

Antimicrob Agents Chemother. 1993 Feb;37(2):293-6.

27.

Fleroxacin: a review of its chemistry, microbiology, toxicology, pharmacokinetics, clinical efficacy and safety.

Cullmann W, Geddes AM, Weidekamm E, Urwyler H, Braunsteiner A.

Int J Antimicrob Agents. 1993;2(4):203-30. No abstract available.

PMID:
18611535
28.

Penetration of fleroxacin into human and animal tissues.

Portmann R, Weidekamm E.

Chemotherapy. 1992;38(3):145-9.

PMID:
1511632
29.

Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.

Hayton WL, Vlahov V, Bacracheva N, Viachki I, Portmann R, Muirhead G, Stoeckel K, Weidekamm E.

Antimicrob Agents Chemother. 1990 Dec;34(12):2375-80. Erratum in: Antimicrob Agents Chemother 1991 May;35(5):1017.

30.

Fleroxacin concentrations in myometrium, ovary and fallopian tube.

Portmann R, Hansz C, Stiglmayer R, Weidekamm E.

J Antimicrob Chemother. 1989 Apr;23(4):662-4. No abstract available.

PMID:
2501273
32.

Multiple intravenous dose pharmacokinetic study of carumonam in healthy subjects.

Patel IH, Soni PP, Portmann R, Suter K, Banken L, Weidekamm E.

J Antimicrob Chemother. 1989 Jan;23(1):107-11.

PMID:
2745245
33.

Single and multiple dose pharmacokinetics of fleroxacin.

Weidekamm E, Portmann R, Partos C, Dell D.

J Antimicrob Chemother. 1988 Oct;22 Suppl D:145-54.

PMID:
3144533
34.

Plasma concentrations of sulfadoxine in healthy and malaria infected Thai subjects.

Sarikabhuti B, Keschamrus N, Noeypatimanond S, Weidekamm E, Leimer R, Wernsdorfer W, Kölle EU.

Acta Trop. 1988 Sep;45(3):217-24.

PMID:
2903623
35.

Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.

Weidekamm E, Portmann R, Suter K, Partos C, Dell D, Lücker PW.

Antimicrob Agents Chemother. 1987 Dec;31(12):1909-14.

36.

Pharmacokinetics of Ro 23-6240 (AM 833), a new trifluorinated quinolone.

Weidekamm E, Stöckel K, Dell D.

Chemioterapia. 1987 Jun;6(2 Suppl):307-8. No abstract available.

PMID:
3151346
37.

Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef.

Weidekamm E, Schwartz DE, Dubach UC, Weber B.

Chemotherapy. 1987;33(4):259-65.

PMID:
3608626
38.

Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects.

Schwartz DE, Weidekamm E, Mimica I, Heizmann P, Portmann R.

Chemotherapy. 1987;33(1):1-8.

PMID:
3493885
39.

A new trifluorinated quinolone: Ro 23-6240 (AM 833).

Weidekamm E, Stöckel K, Dell D.

Drugs Exp Clin Res. 1987;13(2):85-90.

PMID:
3107959
40.

Pharmacokinetics of carumonam in patients with renal insufficiency.

Horber F, Egger HJ, Weidekamm E, Dubach UC, Frey FJ, Probst PJ, Stoeckel K.

Antimicrob Agents Chemother. 1986 Jan;29(1):116-21.

41.

Pharmacokinetics of tenoxicam in patients with impaired renal function.

Horber FF, Guentert TW, Weidekamm E, Heizmann P, Descoeudres C, Frey FJ.

Eur J Clin Pharmacol. 1986;29(6):697-701.

PMID:
3709612
42.

Absence of pharmacokinetic interaction between Fansidar and mefloquine.

Schwartz DE, Weidekamm E, Ranalder VB, Dubach VC, Forgo I, Weber B.

Trans R Soc Trop Med Hyg. 1986;80(6):1001-2. No abstract available.

PMID:
3496691
43.

Single-dose pharmacokinetics of Ro 17-2301 (AMA-1080), a monocyclic beta-lactam, in humans.

Weidekamm E, Stoeckel K, Egger HJ, Ziegler WH.

Antimicrob Agents Chemother. 1984 Dec;26(6):898-902.

45.

Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting.

Weidekamm E, Plozza-Nottebrock H, Forgo I, Dubach UC.

Bull World Health Organ. 1982;60(1):115-22.

46.

Raman and infrared spectroscopic study of gramicidin A conformations.

Iqbal Z, Weidekamm E.

Arch Biochem Biophys. 1980 Jul;202(2):639-49. No abstract available.

PMID:
6161581
47.

Pre-resonance Raman spectra and conformations of nystatin in powder, solution and phospholipid-cholesterol multilayers.

Iqbal Z, Weidekamm E.

Biochim Biophys Acta. 1979 Aug 23;555(3):426-35. No abstract available.

PMID:
486460
48.

Laser-Raman study of valinomycin-doped and omega-CD3-labeled phosphatidylcholine liposomes.

Weidekamm E, Bamberg E, Janko K, Weber R.

Arch Biochem Biophys. 1978 Apr 30;187(2):339-45. No abstract available.

PMID:
580861
49.

Phospholipid composition of human erythrocyte spectrin.

Weidekamm E, Brdiczka B, Wildermuth M.

Mol Biol Rep. 1978 Feb 28;4(1):25-8.

PMID:
642938
50.

Biochemical characterization of segreated membrane vesicles from human erythrocytes with increased intracellular Ca2+.

Weidekamm E, Brdiczka D, Di Pauli G, Wildermuth M.

Arch Biochem Biophys. 1977 Mar;179(2):486-94. No abstract available.

PMID:
851355

Supplemental Content

Loading ...
Support Center